SCHEMBL29391320

SCHEMBL29391320

CN1CCc2ccccc2CC1

nearest known ligand 0.85

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ DRD1 P21728 14/20 0.85
▸ DRD5 P21918 13/20 0.85
▸ DRD2 P14416 12/20 0.85
▸ DRD3 P35462 11/20 0.85
▸ DRD4 P21917 9/20 0.85
▸ MAOA P21397 2/20 0.85
▸ MAOB P27338 2/20 0.85
▸ ADRA2A P08913 2/20 0.56
▸ ADRA1A P35348 2/20 0.56
▸ SETD7 Q8WTS6 2/20 0.56
▸ CYP2D6 P10635 1/20 0.56
▸ ADRA2B P18089 1/20 0.56
▸ ADRA2C P18825 1/20 0.56
▸ ADRA1D P25100 1/20 0.56
▸ ADRA1B P35368 1/20 0.56
▸ CHRM2 P08172 1/20 0.55
▸ HTR1A P08908 1/20 0.55
▸ CHRM1 P11229 1/20 0.55
▸ SLC6A2 P23975 1/20 0.55
▸ SLC6A4 P31645 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL164206 1.00 DRD1 (0.85) DRD1DRD5DRD2DRD3DRD4
Iodide SCHEMBL12468173 0.97 DRD1 (0.81) DRD1DRD5DRD2DRD3DRD4
Hydrochloric Acid SCHEMBL165521 0.97 MAOA (0.86) DRD1DRD5DRD2DRD3DRD4
SCHEMBL29390912 0.92 MAOA (1.00) DRD1DRD5DRD2DRD3DRD4
SCHEMBL98108 0.92 MAOA (1.00) DRD1DRD5DRD2DRD3DRD4
Hydrochloric Acid SCHEMBL23501375 0.90 MAOA (1.00) DRD1DRD5DRD2DRD3DRD4
SCHEMBL7973918 0.90 DRD1 (0.71) DRD1DRD5DRD2DRD3DRD4
SCHEMBL4320673 0.88 MAOA (0.91) DRD1DRD5DRD2DRD3DRD4
Sulfuric Acid SCHEMBL174314 0.86 DRD1 (0.65) DRD1DRD5DRD2DRD3DRD4
SCHEMBL28072797 0.84 MAOA (0.83) DRD1DRD5DRD2DRD3DRD4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230250080-A1 ENZYME INHIBITORS KALVISTA PHARMACEUTICALS LTD (GB) 2023-08-10 — — US disclosed
US-11613527-B2 Enzyme inhibitors KALVISTA PHARMACEUTICALS LIMITED (GB) 2023-03-28 — — US disclosed
US-20220048894-A1 ENZYME INHIBITORS KALVISTA PHARMACEUTICALS LIMITED (GB) 2022-02-17 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230250080-A1 ENZYME INHIBITORS SERPINB1, KLKB1, SERPINE1 DRD1 4401/4885DRD5 3837/4885DRD2 4189/4885
US-11613527-B2 Enzyme inhibitors SERPINB1, KLKB1, SERPINE1 DRD1 4401/4885DRD5 3837/4885DRD2 4189/4885
US-20220048894-A1 ENZYME INHIBITORS SERPINB1, KLKB1, SERPINE1 DRD1 4401/4885DRD5 3837/4885DRD2 4189/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback